Citations

Clear

900 citation(s) found for "Martinez, F J".

Technology-Enabled Skin Longevity Optimization
Vyas, Krishna S. , Ansaf, Ryeim B. , Martinez-Jorge, Jorys, Tarbet, Kristin, Wyles, Saranya P.

Mayo Clinic

Facial Plastic Surgery | November 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-3005-2229 | PMID 43051260 Get It

Aims and Backgrounds: Facial aging is a multifactorial process involving cellular senescence, ultraviolet damage, and structural decline across the epidermis, dermis, subcutaneous fat, and superficial musculoaponeurotic system. Contemporary rejuvenation has evolved beyond surgical repositioning toward biologically targeted cutaneous optimization. Technology: Energy-based technologies including laser photothermolysis, radiofrequency-mediated dermal thermomodulation, microfocused ultrasound, and emerging microwave and cryobiologic modalities induce controlled tissue injury that activates wound-healing pathways, fibroblast proliferation, and extracellular matrix remodeling. Techniques: Regenerative strategies including microneedling-assisted mechanotransduction, platelet-derived biologics, autologous fat grafting, collagen biostimulators, and extracellular vesicle therapies provide biologically oriented tissue restoration through paracrine signaling and matrix synthesis. Current and Future Development: Artificial intelligence applications in facial phenotyping, treatment planning, and outcome assessment are emerging. Future directions include senescence-targeting therapies and precision-based multimodal protocols. Conclusions and Clinical Relevance: Multimodal treatment sequencing addressing multiple anatomical layers represents the contemporary standard. Integration of device-based technologies with regenerative adjuncts enables biologically informed, individualized facial rejuvenation.
Oral Cellular Neurothekeoma: Case Report and Brief Review of the Literature
Martínez, Sofia Carolin , Masatkar, Vaishali

Mayo Clinic

The American Journal of Dermatopathology | November 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dad.0000000000003475 | PMID 43037609 Get It

Introduction: Cellular neurothekeoma (CNT) is a rare benign mesenchymal neoplasm of uncertain histogenesis distinct from dermal nerve sheath myxoma. Oral involvement is exceedingly uncommon. Case presentation: A 22-year-old woman presented with a 5-month history of a painful enlarging intraoral mass involving the left buccal and labial gingiva, associated with difficulty eating and speaking. Imaging revealed an ill-defined soft tissue mass without bone involvement. An initial excisional biopsy was interpreted as nodular fasciitis. After recurrence at 6 months, conservative resection was performed. Histopathologic evaluation demonstrated a multilobular submucosal neoplasm composed of spindle to epithelioid cells arranged in fascicular and nodular patterns within a myxoid stroma, separated by hyaline collagen, with admixed lymphoplasmacytic inflammation. Tumor cells were negative for S100, cytokeratin AE1/AE3, desmin, CD34, EMA, and ALK, with focal positivity for SMA and PGP9.5. Ki-67 showed a low proliferative index (<5%). Molecular testing was negative for USP6 gene rearrangement. These findings supported a diagnosis of CNT. Conclusion: We report the 10th case of oral CNT, highlighting the importance of comprehensive histologic, immunohistochemical, and molecular evaluation to avoid misdiagnosis.
Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Zanwar, Saurabh S , Hansen, Doris K , Tan, Carlyn R , Peres, Lauren C , Popat, Rakesh , Afrough, Aimaz , Asoori, Sireesha , Dave, Mrugakshi , Portuguese, Andrew J , Kastritis, Efstathios , Davis, James A , Martinez-Lopez, Joaquin , Sborov, Douglas W , Mihalyova, Jana , Bal, Susan , Janakiram, Murali , Ferreri, Christopher , Biran, Noa , Herr, Megan M. , Grajales-Cruz, Ariel F , Khouri, Jack , Castaneda Puglianini, Omar , Liang, Emily C , Zolotov, Eli , Galarza Fortuna, Gliceida M , Julian, Kelley L , Sannareddy, Aishwarya , Anderson, Larry D , Raza, Shahzad , Dima, Danai , Anwer, Faiz , Kumar, Shaji K , Usmani, Saad , Huang, Chiung-Yu , Mian, Hira , Sidana, Surbhi , Patel, Krina , Lin, Yi , Costa, Luciano J

Mayo Clinic

Journal of Clinical Oncology | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01039 | PMID 43024836 Get It

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Rise of AI-assisted personal statements and letters of recommendation in pain medicine fellowship applications
Yavuz-Kivanc, Tugba, Kanahan-Osman, Sharima , Eldrige, Jason , Kubrova, Eva , Hunt, Christine , Martinez, Fiorela

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: rapm-2026-108629

10.1136/rapm-2026-108629 | PMID 42946398 Get It

Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review
Patel, Shivam , Gandhi, Akash , Pabani, Arman , Shah, Richa , Shah, Pal , Martinez, Matthew W , Bavishi, Aakash

Mayo Clinic

Journal of the American Heart Association | October 23, 2026 | Volume: 15 | Issue: 21 | Pages: No page available

10.1161/jaha.126.051256 | PMID 42924841 Get It

Background Nonobstructive hypertrophic cardiomyopathy (HCM) affects approximately one‐third of all patients with HCM and carries substantial morbidity, yet no approved disease‐modifying therapies exist. We conducted a systematic review of prospective interventional studies evaluating pharmacologic therapies in adults with nonobstructive HCM. Methods A systematic search of PubMed, Cochrane Central Register of Controlled Trials, and Clinicaltrials.gov was performed through September 2025. Eligible studies included randomized and nonrandomized prospective interventional trials. A narrative synthesis was performed by pharmacologic class and outcome domain. Results Twenty‐nine clinical trials evaluating 9 pharmacologic classes were identified: cardiac myosin inhibitors, cardiac sarcomere modulators, metabolic modulators, angiotensin II receptor blockers, angiotensin receptor‐neprilysin inhibitors, mineralocorticoid receptor antagonists, SGLT2 (sodium‐glucose cotransporter 2) inhibitors, beta blockers, and calcium channel blockers. Cardiac myosin inhibitors demonstrated reductions in left ventricular hypertrophy, improvements in diastolic function, and marked reductions in cardiac biomarkers, although improvements in exercise capacity and symptoms were variable. SGLT2 inhibition showed concordant improvements in diastolic function, atrial remodeling, biomarkers, and functional status in patients with symptomatic nonobstructive HCM and comorbid type 2 diabetes. Angiotensin receptor blockade showed signals of structural remodeling with valsartan and candesartan without consistent functional benefit. Mineralocorticoid receptor antagonism and angiotensin receptor‐neprilysin inhibition demonstrated largely neutral effects. Among metabolic modulators, ninerafaxstat improved ventilatory efficiency and quality of life in patients with greater baseline symptom burden. Conclusions Pharmacologic responsiveness in nonobstructive HCM is variable and appears to be mechanism‐ and disease stage‐dependent. Ongoing trials evaluating cardiac myosin inhibitors, SGLT inhibitors, and novel therapeutic agents including ninerafaxstat and EDG‐7500 will be critical in further defining the therapeutic landscape.
An artificial intelligence algorithm characterizes the deterioration of body composition from systemic therapy for patients with advanced prostate cancer
Martinez, Gianni Morales, O'Byrne, Jamie, Weston, Alexander, Grossardt, Brandon, Gettman, Matthew T., Andrews, Jack

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag349 | PMID 42826502 Get It

Abstract Skeletal muscle is a major determinant of functional status. The impact of advanced prostate cancer (aPC) systemic therapies on body composition is unknown. We identified aPC patients with serial PET-CTs receiving androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPI), chemotherapy, and/or Lutetium-177. An artificial intelligence algorithm quantified body composition changes from PET-CT images. Linear mixed effects models examined body composition changes over time by treatment type. The algorithm examined 2,342 PET-CTs from 468 patients. On multivariable analysis, ADT was associated with a 9% reduction in muscle density (-1.91 Hounsfield units), ARPIs an additional 6% (-1.4 Hounsfield units), and Lutetium-177 a subsequent 6% (-1.3 Hounsfield units), demonstrating progressive reduction in muscle density across later stages of systemic therapy. This large longitudinal analysis of body composition in aPC patients supports the use of an automated PET-CT algorithm to identify aPC patients on systemic therapy at risk for muscle wasting.
Impact of obesity on surgical and patient-reported outcomes after masculinizing chest surgery: a systematic review and meta-analysis
Machado, Guilherme Franceschini , Matos de Albuquerque, Karine, Barros Magalhães, Caio Augusto, Gomes, Ana Carolina dos Santos, Queiroz Ferreira, Maria Fernanda , de Carvalho Lacerda, Henrique, Carvalho Silva, Arthur , Kreutz-Rodrigues, Lucas, Liang, Fan, Martinez‐Jorge, Jorys, Albuquerque, Karine Matos de , Lacerda, Henrique de Carvalho, Kreutz‐Rodrigues, Lucas , Liang, Fan

Mayo Clinic

International Journal of Transgender Health | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-18

10.1080/26895269.2026.2732195 Get It

Pearls & Oy-sters: DPPX Antibody-Associated Encephalitis in a Patient With Diarrhea, Tremor, Ocular Flutter, and Cognitive-Psychiatric Changes
Sosa, Santiago Martinez , Webb, Lauren M. , Thomsen, Anna, Rigler, Nicole, Coon, Elizabeth A. , Toledano, Michel , McKeon, Andrew , Banks, Samantha A. , Martinez Sosa, Santiago , Paz Soldán, M Mateo , Coon, Elizabeth Anne , Toledano, Michel , McKeon, Andrew , Syc-Mazurek, Stephanie B , Banks, Samantha , Soldán, M. Mateo Paz , Syc‐Mazurek, Stephanie B.

Mayo Clinic

Neurology | September 1, 2026 | Volume: 107 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000218522 | PMID 42679339 Get It

OA07.2. Baseline Mucosal Impedance on High-Resolution Impedance Manometry Distinguishes Active From Inactive Eosinophilic Esophagitis
Martinez, Josealberto Arenas, Freeman, Catherine, Crowell, Michael, Vela, Marcelo, Wright, Benjamin, Horsley-Silva, Jennifer, Wang, Fangfang, Arenas-Martínez, Josealberto S., Freeman, Catherine , Crowell, Michael D. , Vela, Marcelo F. , Horsley‐Silva, Jennifer L.

Mayo Clinic

Diseases of the Esophagus | August 22, 2026 | Volume: 39 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doag077.050 Get It

Abstract Topic Benign Disease: Eosinophilic Esophagitis Background Active inflammation in eosinophilic esophagitis (EoE) disrupts the mucosal barrier, leading to dilated intercellular spaces and decreased transepithelial electrical resistance. Mucosal impedance (MI) has been used to assess mucosal integrity in EoE. We evaluated whether baseline MI measured by high-resolution impedance manometry (HRIM) distinguishes active and inactive EoE. Methods We retrospectively reviewed data from patients with EoE who underwent endoscopic esophageal biopsies within three months of HRIM from 2018-2026 at our tertiary referral center and had no treatment changes between studies. We excluded patients with a history of foregut surgery, erosive esophagitis, or Barrett’s esophagus. Demographics, endoscopy and pathology results were collected by chart review. Active EoE was histologically defined as ≥15 eosinophils per high-power field. Esophageal baseline MI was measured in the 30-second landmark period for the whole esophagus (from 2 cm above LES to 2 cm below UES), distal esophagus (from 2–7 cm above LES), and mid/proximal esophagus (from 10 cm above LES to 2 cm below UES). Mann–Whitney U or T tests were used for comparisons . Optimal MI thresholds were identified by Youden index with 10,000 bootstrap validations, and interrater reliability was assessed using two-way mixed effects intraclass correlation coefficients. Results Seventy-three patients were included: 37 (51%) female, median age 52 years, median BMI 27.2 kg/m2. Fifty-seven patients (78%) had atopic history, including seasonal allergies (38, 52%), asthma (31, 42%), eczema (21, 29%), and food allergies (19, 26%). Thirty-nine patients (53%) were receiving proton pump inhibitors, 25 (34%) were not on EoE therapy, 5 (6.8%) were on swallowed topical steroids, 3 (4.1%) were on dupilumab, and 1 (1.4%) was on an elimination diet. Esophageal strictures were present in 23 patients (32%), and 45 (62%) had active EoE. Baseline MI measurement showed high interrater reliability (n=50, 2 raters; intraclass correlation coefficient 0.937–0.963, p&lt;0.001). Basal mean and minimal impedance were significantly lower in active EoE across all segments, greatest in the distal esophagus (all p&lt;0.05; Figure 1). ROC analysis showed high discrimination of distal mean MI, with a cutoff ≤1.91 kΩ (AUC=0.837, sensitivity 67.9%, specificity 86.7%, Youden 0.545; Figure 2). Conclusion Baseline mucosal impedance during HRIM distinguishes active from inactive EoE, with strongest discrimination in the distal esophagus, supporting MI as a potential, minimally-invasive physiologic marker of mucosal inflammation and disease activity. Clinically, MI may serve as an adjunct tool in dysphagia evaluation, prompting EoE-directed biopsy when abnormal, aiding management in biopsy–symptom discordance, and potentially supporting disease monitoring in selected patients. Larger prospective studies are warranted.